Merck & Co.'s (MRK.US) new drug for pulmonary arterial hypertension has been submitted for approval in China.

On October 17, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE)'s website showed that Merck (MRK.US) had received a notice of acceptance for its application for the marketing authorization of subcutaneous sotatercept. According to public information, it is a "first-in-class" new biological agent that inhibits the activin signal. The product was approved for marketing in the United States by the FDA in March this year and is used to treat pulmonary arterial hypertension (PAH). This therapy was previously rated by industry media Evaluate as one of the potential blockbuster therapies in 2024.